TO DOWNLOAD THE DATASET, CLICK ON THE "Download" BUTTON

THIS DATA HAS BEEN REPLACED BY DIFFERENT FEATURE SERVICESTHE LAST DATE OF ENTRY WAS 8/23/2020THE DATA REPLACING THIS DATA CAN BE FOUND:SAMHD Daily Surveillance Data PublicSAMHD COVID-19 Weekly Data PublicCOVID19 Weekly Lab Testing Public------------------------------------------------------------------------------------------------------------------------------------------------------This data set contains data used to produce the public CoVID-19 Surveillance Dashboard and describes a variety of indicators of the CoVID-19 situation in the City of San Antonio and Bexar County. Each field is updated daily since the first date the data element appeared live in the Dashboard. The Surveillance Dashboard is live and available here.This data reflects information provided by the City of San Antonio Metro Health Department, and is released daily at 7PM on the City of San Antonio CoVID-19 website.

TO DOWNLOAD THE DATASET, CLICK ON THE "Download" BUTTON

TO DOWNLOAD THE DATASET, CLICK ON THE "Download" BUTTON

{{description}}

TO DOWNLOAD THE DATASET, CLICK ON THE "Download" BUTTON

{{description}}

The City of San Antonio's Open Data page for CoVID-19 surveillance data.

The City of San Antonio's Open Data page for CoVID-19 vaccination data.

TO DOWNLOAD THE DATASET, CLICK ON THE "Download" BUTTON

United States AQI: Texas: San Antonio-New Braunfels: PM10 data was reported at 44.000 Index in 16 May 2025. This records an increase from the previous number of 43.000 Index for 15 May 2025. United States AQI: Texas: San Antonio-New Braunfels: PM10 data is updated daily, averaging 18.000 Index from Mar 1985 (Median) to 16 May 2025, with 6027 observations. The data reached an all-time high of 141.000 Index in 04 Mar 2025 and a record low of 1.000 Index in 12 Dec 2007. United States AQI: Texas: San Antonio-New Braunfels: PM10 data remains active status in CEIC and is reported by United States Environmental Protection Agency. The data is categorized under Global Database’s United States – Table US.ESG.E: Air Quality Index and Air Pollutants. [COVID-19-IMPACT]

Background: Limited information is available for patients with breast cancer (BC) and coronavirus disease 2019 (COVID-19), especially among underrepresented racial/ethnic populations. Methods: This is a COVID-19 and Cancer Consortium (CCC19) registry-based retrospective cohort study of females with active or history of BC and laboratory-confirmed severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection diagnosed between March 2020 and June 2021 in the US. Primary outcome was COVID-19 severity measured on a five-level ordinal scale, including none of the following complications, hospitalization, intensive care unit admission, mechanical ventilation, and all-cause mortality. Multivariable ordinal logistic regression model identified characteristics associated with COVID-19 severity. Results: 1,383 female patient records with BC and COVID-19 were included in the analysis, the median age was 61 years, and median follow-up was 90 days. Multivariable analysis revealed higher odds of COVID-19 severity for older age (aOR per decade, 1.48 [95% CI, 1.32–1.67]); Black patients (aOR 1.74; 95 CI 1.24–2.45), Asian Americans and Pacific Islander patients (aOR 3.40; 95 CI 1.70–6.79) and Other (aOR 2.97; 95 CI 1.71–5.17) racial/ethnic groups; worse ECOG performance status (ECOG PS ≥2: aOR, 7.78 [95% CI, 4.83–12.5]); pre-existing cardiovascular (aOR, 2.26 [95% CI, 1.63–3.15])/pulmonary comorbidities (aOR, 1.65 [95% CI, 1.20–2.29]); diabetes mellitus (aOR, 2.25 [95% CI, 1.66–3.04]); and active and progressing cancer (aOR, 12.5 [95% CI, 6.89–22.6]). Hispanic ethnicity, timing, and type of anti-cancer therapy modalities were not significantly associated with worse COVID-19 outcomes. The total all-cause mortality and hospitalization rate for the entire cohort were 9% and 37%, respectively; however, it varied according to the BC disease status. Conclusions: Using one of the largest registries on cancer and COVID-19, we identified patient- and BC-related factors associated with worse COVID-19 outcomes. After adjusting for baseline characteristics, underrepresented racial/ethnic patients experienced worse outcomes compared to Non-Hispanic White patients.

Context

Multisystem inflammatory syndrome in children (MIS-C), also known as pediatric inflammatory multisystem syndrome, is a new dangerous childhood disease that is temporally associated with coronavirus disease 2019 (COVID-19). We aimed to describe the typical presentation and outcomes of children diagnosed with this hyperinflammatory condition.

https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(20)30271-6/fulltext#seccesectitle0001

Content

A systematic review to communicate the clinical signs and symptoms, laboratory findings, imaging results, and outcomes of individuals with MIS-C.

Acknowledgements

Authors: Mubbasheer Ahmeda;; , Shailesh Advanib;; Axel Moreira;; , Sarah Zoretic;; , John Martinez;; Kevin Chorath;; , Sebastian Acosta;; , Rija Naqvi;; Finn Burmeister-Morton;; Fiona Burmeister;; Aina Tarriela;; , Matthew Petershack;; , Mary Evans;; , Ansel Hoang;; Karthik Rajasekaran;; , Sunil Ahuja;; Alvaro Moreira

Department of Pediatrics, Texas Children’s Hospital, Houston, TX, USA;; Department of Oncology, Georgetown University, Washington, DC, USA;; Social Behavioral Research Branch, National Human Genome Research Institute, National Institutes of Health, USA;; Department of Pediatrics, University of Texas Health Science Center San Antonio, San Antonio, TX 78229-3900, USA;; Department of Otorhinolaryngology, The University of Pennsylvania, Philadelphia, PA, USA.

Photo by L N on Unsplash

Inspiration

Covid-19 Pandemic.

Background: The burden of the COVID-19 pandemic in Peru has led to people seeking alternative treatments as preventives and treatment options such as medicinal plants. This study aimed to assess factors associated with the use of medicinal plants as preventive or treatment of respiratory symptom related to COVID-19 during the pandemic in Cusco, Peru.

Method: A web-based cross-sectional study was conducted on general public (20- to 70-year-old) from August 31 to September 20, 2020. Data were collected using a structured questionnaire via Google Forms, it consisted of an 11-item questionnaire that was developed and validated by expert judgment using Aiken's V (Aiken's V > 0.9). Both descriptive statistics and bivariate followed by multivariable logistic regression analyses were conducted to assess factors associated with the use of medicinal plants for COVID-19 prevention and respiratory symptom treatment during the pandemic. Prevalence ratios (PR) with 95% Confidence Interval (CI), and a P-value of 0.05 was used to determine statistical significance.

Results: A total of 1,747 respondents participated in the study, 80.2% reported that they used medicinal plants as preventives, while 71% reported that they used them to treat respiratory symptoms. At least, 24% of respondents used medicinal plants when presenting with two or more respiratory symptoms, while at least 11% used plants for malaise. For treatment or prevention, the multivariate analysis showed that most respondents used eucalyptus (p ​​< 0.001 for both), ginger (p​​ < 0.022 for both), spiked pepper (p < 0.003 for both), garlic (p = 0.023 for prevention), and chamomile (p = 0.011 for treatment). The respondents with COVID-19 (p < 0.001), at older ages (p = 0.046), and with a family member or friend who had COVID-19 (p < 0.001) used more plants for prevention. However, the respondents with technical or higher education used less plants for treatment (p < 0.001).

Conclusion: There was a significant use of medicinal plants for both prevention and treatment, which was associated with several population characteristics and whether respondents had COVID-19.

Methods We conducted an online cross-sectional multicenter survey, which was initially evaluated by 10 expert judges using Aiken's V (40). After including the experts’ observations, a pilot study was performed (from August 16 to 4) with 336 respondents in in five districts of Cusco, Peru. The pilot data was used to calculate the minimal sample size necessary for the actual study. It was determined that a minimum sample size of 1,530 was necessary to achieve a minimum percentage difference of 2.5% (49.0% versus 51.5%), a statistical power of 80%, and a confidence level of 95%. The sample size was calculated using power analysis.

The actual survey consisted of an online questionnaire that was sent via WhatsApp, Messenger, and Facebook. The shared questionnaire was made anonymous ensuring data confidentiality and reliability. The survey was performed from August 31 to September 20, 2020 after approximately 9 months of lockdown and social distancing measures in Peru due to the COVID-19 outbreak. At the beginning of the survey (August 31) the number of COVID-19 confirmed cases was 652,037 and 28,944 deaths, while at the end of the survey (September 20) the confirmed cases increased to 772,896 and the deaths increased to 31,474. We surveyed general public who were adults of both genders aged 20 to 70 years in five districts of Cusco, Peru with high-risk COVID-19 transmission according to the Epidemiological Alert AE-017-2020. The five districts were Cusco, San Jerónimo, San Sebastián, Santiago, and Wanchaq. Participants were recruited by the research team of the Universidad Nacional de San Antonio Abad del Cusco.

United States AQI: Texas: San Antonio-New Braunfels: NO2 data was reported at 40.000 Index in 31 Jan 2025. This records a decrease from the previous number of 41.000 Index for 30 Jan 2025. United States AQI: Texas: San Antonio-New Braunfels: NO2 data is updated daily, averaging 16.000 Index from Jan 1980 (Median) to 31 Jan 2025, with 11998 observations. The data reached an all-time high of 54.000 Index in 01 Dec 2017 and a record low of 1.000 Index in 28 Jun 2020. United States AQI: Texas: San Antonio-New Braunfels: NO2 data remains active status in CEIC and is reported by United States Environmental Protection Agency. The data is categorized under Global Database’s United States – Table US.ESG.E001: Air Quality Index and Air Pollutants. [COVID-19-IMPACT]